Form 4: Cidara Therapeutics Executive Taylor Sandison Reports Acquisition of Restricted Stock Units and Stock Options

Taylor Sandison, Chief Medical Officer of Cidara Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• On March 15, 2024, Taylor Sandison, Chief Medical Officer of Cidara Therapeutics, acquired 128,750 shares of common stock in the form of Restricted Stock Units (RSUs) and an option to purchase 235,500 shares of common stock.
• The RSUs were granted at a price of $0 per share.
• These RSUs vest in three equal annual installments starting March 10, 2025, and continuing in 2026 and 2027, contingent upon continuous service.
• Sandison also acquired an employee stock option to buy 235,500 shares at an exercise price of $0.6849.
• The stock options vest in 36 equal monthly installments from March 15, 2024.
• Following these transactions, Sandison directly owns 475,845 shares of common stock and options to purchase 235,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of granting stock options and RSUs to an executive. This is generally seen as a positive sign of aligning management interests with shareholders, but it's a routine event.

Positives

• The granting of RSUs and stock options to the Chief Medical Officer aligns their interests with the long-term success of the company.
• The vesting schedules for both RSUs and stock options incentivize continued service and contribution to Cidara Therapeutics.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The granting of RSUs and stock options can positively impact shareholders by aligning management's interests with the company's long-term performance.

Key Dates